ARTICLE | Clinical News
Norditropin regulatory update
November 10, 2008 8:00 AM UTC
FDA approved an sNDA from Novo Nordisk to expand the label for Norditropin to include treatment of children with short stature born small for gestational age with no catch-up growth by age 2-4 years. ...